SeekingAlpha · Sep 9, 2026
BI
NASDAQ · BIOA
BioAge Labs, Inc.
Healthcare · Biotechnology
$7.75
Down-$0.43 (-5.26%)
Updated Sep 17, 2026, 10:22 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 458.05M
- P/E ratio
- -6.04
- Dividend yield
- 0.00%
- 52-week range
- $8.02 – $25.96
- Volume
- 715.82K
- Avg. volume
- 403.63K
Price performance
BIOA price history
1M range · 20 trading sessions · Daily adjusted prices
BIOA closed at $7.75 after 20 trading sessions, down 27.91% for the selected period.
- Last close
- $7.75
- Period change
- -27.91%
- Period low
- $7.75
- Period high
- $10.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $8.21 | $8.275 | $7.62 | $7.75 | 715.82K |
| Sep 15, 2026 | $8.48 | $8.50 | $8.02 | $8.18 | 643.57K |
| Sep 14, 2026 | $8.52 | $8.635 | $8.39 | $8.48 | 563.39K |
| Sep 11, 2026 | $8.71 | $8.89 | $8.28 | $8.49 | 672.08K |
| Sep 10, 2026 | $9.07 | $9.07 | $8.60 | $8.65 | 492.87K |
| Sep 9, 2026 | $9.38 | $9.40 | $9.02 | $9.17 | 488.35K |
| Sep 8, 2026 | $9.60 | $9.645 | $9.3239 | $9.395 | 388.07K |
| Sep 4, 2026 | $9.39 | $9.76 | $9.39 | $9.59 | 314.85K |
| Sep 3, 2026 | $9.90 | $9.98 | $9.415 | $9.50 | 407.28K |
| Sep 2, 2026 | $9.59 | $10.05 | $9.425 | $9.73 | 541.26K |
| Sep 1, 2026 | $9.28 | $9.72 | $9.1501 | $9.52 | 605.31K |
| Aug 31, 2026 | $9.61 | $9.63 | $9.20 | $9.50 | 1.03M |
| Aug 28, 2026 | $10.06 | $10.25 | $9.595 | $9.65 | 452.19K |
| Aug 27, 2026 | $9.93 | $10.23 | $9.80 | $10.08 | 475.43K |
| Aug 26, 2026 | $10.03 | $10.03 | $9.76 | $9.84 | 504.28K |
| Aug 25, 2026 | $9.55 | $10.13 | $9.55 | $10.11 | 499.33K |
| Aug 24, 2026 | $9.57 | $9.65 | $9.16 | $9.38 | 661.58K |
| Aug 21, 2026 | $9.78 | $9.9164 | $9.48 | $9.48 | 453.45K |
| Aug 20, 2026 | $10.64 | $10.725 | $9.63 | $9.69 | 776.79K |
| Aug 19, 2026 | $10.69 | $10.88 | $10.38 | $10.75 | 412.25K |
Latest BIOA news
The latest Smart Investors Daily articles mentioning BIOA.
Stock researchCompany · Overview
BIOA research
Overview
Company profile and research snapshot.
Company profile
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Roth Capital | Buy | — |
| Sep 8, 2026 | BTIG | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Aug 3, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 9, 2026
Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target
Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.
Yahoo · Sep 8, 2026
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”),
Benzinga · Sep 8, 2026
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
